Overview

Atropine for Children and Adolescent Myopia Progression Study

Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
0
Participant gender:
All
Summary
Investigators are going to conduct a randomized controlled trial that myopic children are randomly allocated into two groups: combined use of 1% atropine and 0.01% atropine (experimental group) and 0.01% atropine (control group) in order to explore a better way to control myopia progression and eliminate adverse effects at the same time, provide reliably evidence for clinical guideline of atropine use in children, and investigate the mechanism of atropine on eyes.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shanghai Eye Disease Prevention and Treatment Center
Collaborator:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Treatments:
Atropine
Ophthalmic Solutions
Criteria
Inclusion Criteria:

- children aged from 7-12 years old;

- children with spherical equivalent ranged from -0.5D to -6.0D;

- children without other eye diseases except for ametropia

Exclusion Criteria:

- children with other eye diseases: amblyopia, strabismus, eye trauma, etc;

- children with cycloplegia contradictions;

- children who have used atropine;

- children who are severly allergic with atropine;

- children who are using other eye drops for treatment;

- children with severe heart, lung, liver and kidney diseases.